Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects: A retrospective postmortem immunocytochemical and histofluorescent study

Neurology

Volumn 49, Issue 5, 1997, Pages 1306-1311

  Heitner, John ^a   Dickson, Dennis W ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FLUORESCENCE; FLUORESCENCE MICROSCOPY; GLYCATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 0030680107     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.5.1306     Document Type: Article

References (44)

1. Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alterations in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press, 1994:179-196.
2. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. a component of Alzheimer paired helical filaments. J Biol Chem 1986; 261:6084-6089.
3. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991;251:675-678.
4. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (τ) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913-4917.
5. Yen S-H, Liu W-K, Hall FL, Yan S-D, Stern D, Dickson DW. Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Neurobiol Aging 1995; 16:381-387.
6. Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 1994;269:21614-21619.
7. Dickson DW. Pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-339.
8. Younkin SG. Processing of the Alzheimer's disease beta A4 amyloid protein precursor (APP). Brain Pathol 1991;1:253-262.
9. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994;91:5710-5714.
10. Dickson DW, Sinicropi S, Yen S-H, Ko L-W, Mattiace LA, Bucala R, Vlassara H. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging 1996;7:733-743.
11. Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992;13:1-11.
12. He Y, Delaère P, Duyckaerts C, Wasowicz M, Piette F, Hauw JJ. Two distinct ubiquitin immunoreactive senile plaques in Alzheimer's disease: relationship with the intellectual status in 29 cases. Acta Neuropathol 1993;86:109-116.
13. Wang D, Munoz DG. Qualitative and quantitative differences in senile plaque dystrophic neurites of Alzheimer's disease and normal aged brain. J Neuropathol Exp Neurol 1995;54: 548-556.
14. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989;24:173-182.
15. Dickson DW, Ivanushkin A, Heitner J, Yen S-H, Davies P. Apolipoprotein-E immunoreactivity is increased in deposits of Alzheimer's disease, but not pathological aging or diffuse Lewy body disease. In: Iqbal H, Mortimer JA, Winblad B, Wisniewski HM, eds. Research advances in Alzheimer's disease and related disorders. New York: John Wiley & Sons; 1995:371-383.
16. Uchihara T, Duyckaerts C, Lazarini F, et al. Inconstant apolipoprotein E (apoE)-like immunoreactivity in amyloid β protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. Acta Neuropathol 1996;92:180-185.
17. Brownlee M, Cerami A, Vlassara H. Advanced glycation end-products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
18. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;15:1835-1843.
19. Vitek MP, Bhattacharya K, Glenening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994;91:4766-4770.
20. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70:138-151.
21. Harrington CR, Colaco CALS. A glycation connection. Nature 1994;370:247-248.
22. Yan S-D, Chen X, Schmid A-M, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-7790.
23. Yan SD, Yan SF, Chen X, et al. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nature Med 1995;1:693-699.
24. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995;18:172-176.
25. Grill V, Gutniak M, Bjorkman O, et al. Cerebral blood flow and substrate utilization in insulin-treated diabetic subjects. Am J Physiol 1990;258:E813-820.
26. McCall A. The impact of diabetes on the CNS. Diabetes 1992; 41:557-570.
27. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996;39:1392-1397.
28. Curb JD, Rodriguez BL, Petrovitch H, et al. The relationship of diabetes and glucose tolerance to Alzheimer's disease and vascular dementia. Neurobiol Aging 1996;17:S122.
29. Small GW, Rosenthal MJ. Coexistence of Alzheimer's disease and diabetes mellitus. J Am Geriatr Soc 1992;40:1075-1076.
30. Wolf-Klein GP, Siverstone FA, Brod MS, et al. Are Alzheimer patients healthier? J Am Geriatr Soc 1988;36:219-224.
31. Murphy GM Jr, Forno LS, Higgins L, Scardina JM, Eng LF, Cordell B. Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders. Am J Pathol 1994;144:1082-1088.
32. Wolozin BL, Pruchnicki A, Dickson DW, Davies P. A neuronal antigen in the brains of Alzheimer patients. Science 1986;232: 648-650.
33. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
34. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
35. Braak H, Duyckaerts C, Braak E, Piette F. Neuropathological staging of Alzheimer-related changes correlates with psychometrically assessed intellectual status. In: Nicolini M, Zatta PF, Corain B, eds. Alzheimer's disease: advances in clinical and basic research. New York: John Wiley & Sons, 1993:131-137.
36. Mooradian AD. Central nervous system complications of diabetes mellitus - a perspective from the blood brain barrier. Brain Res Rev 1997;23:210-218.
37. Münch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Rev 1997;23:134-143.
38. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
39. Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995;37:254-259.
40. Hendrie HC, Hall KS, Hui S, et al. Apolipoprotein E geno-types and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol 1995;37:118-120.
41. Ogeng'o JA, Cohen DL, Sayi JG, et al. Cerebral amyloid β deposits and other Alzheimer lesions in non-demented elderly East Africans. Brain Pathol 1996;6:101-107.
42. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-691.
43. Roberts KA, Harding JJ. Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose. Exp Eye Res 1990;50:157-164.
44. Munch G, Taneli Y, Schraven E, et al. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycocylation. J Neural Transm Park Dis Dement Sect 1994;8:193-208.